<DOC>
	<DOCNO>NCT02607241</DOCNO>
	<brief_summary>This prospective randomized clinical trial aim compare two different `` metal-free '' strategy elective percutaneous coronary revascularization : FFR-guided DCB-only PCI ( drug-coated balloon : SeQuent Please™ , B Braun Melsungen GmBH ) vs. OCT-guided BRS implantation ( bioresorbable scaffold : Absorb™ , Abbott Vascular ) .</brief_summary>
	<brief_title>Comparison Paclitaxel-Coated Balloons Against Everolimus-Eluting Bioresorbable Scaffolds Elective PCI Using OCT</brief_title>
	<detailed_description>Background : Coronary artery disease ( CAD ) account deaths industrialized country due high prevalence 6-8 % . CAD mainly treat percutaneous coronary intervention ( PCI ) , currently involve 90 % case implantation metallic stent , mostly drug-eluting device ( DES ) . Despite continuous technological advancement last decade , DES still limit long-term follow-up restenosis also risk thrombosis , occur 5-20 % respectively 0.5-1.7 % case . Therefore , two metal-free strategy evaluate order overcome intrinsic limitation DES : 1 . Bioresorbable scaffold ( BRS ) prove comparable safety efficacy 1 year compare best-in-class DES comparators also show small substudies promise 5-year result restoration vasomotricity positive vessel remodel . Optical coherence tomography ( OCT ) new gold standard endovascular imaging stent , atherosclerosis progression , vulnerable plaque neointimal proliferation . OCT currently recommend guidance implantation assessment long-term result BRS . 2 . Drug-coated balloon ( DCB ) mainly employ treat restenosis metallic stent , new report advocate potential used stand-alone treatment de-novo stenosis without stenting , especially fractional flow reserve ( FFR ) measurement additionally use assess PCI result . This clinical trial evaluate FFR-guided DCB-only ( experimental arm : SeQuent Please™ , B Braun Melsungen GmBH ) PCI OCT-guided BRS implantation ( comparator arm : Absorb™ , Abbott Vascular ) treatment stable CAD . The trial design non-inferiority , nationally conduct , multicenter , open-labeled , control study use 1:1 block randomization invasive 6-9 month follow-up ( f/u ) quantitative coronary angiography ( QCA ) OCT . Beyond pre-specified endpoint study mainly look suppression neointimal proliferation , also investigate pattern heal neointimal proliferation , plaque morphology neoatherosclerosis f/u use OCT 6-9 month . Clinically , attempt record major adverse cardiovascular event ( MACE : acute myocardial infarction , cardiac death , TLR ) 5 year index procedure . A number 196 patient schedule PCI native coronary stenosis suitable BRS implantation OCT image openly 1:1 randomize . This number patient consider sufficient prove non-inferiority DCB-only vs. BRS , use margin 0.2 mm confidence interval 0.5 mm primary endpoint ( diameter NLG ) .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>write consent indication elective PCI de novo coronary stenosis native vessel coronary multivessel disease clinically proven indication repeat coronary angiography 69 month ( stag PCI strategy ) pregnancy , lactation , woman childbearing age w/o reliable contraception life expectance &lt; 50 % 1 year major surgery plan within 6 month participation clinical trial impossibility give write consent acute coronary syndrome cardiogenic shock within last 4 week stent thrombosis , define `` probable '' `` definite '' ARC contraindication dual antiplatelet therapy allergy mTORinhibitors taxol derivates target lesion situate leave main coronary artery , bypass graft graft vessel reference luminal diameter target lesion &gt; 3.75 mm &lt; 2.0 mm lesion length &gt; 30 mm , bifurcation lesion require intervention major side branch</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>drug-coated balloon</keyword>
	<keyword>bioresorbable scaffold</keyword>
	<keyword>fractional flow reserve</keyword>
	<keyword>optical coherence tomography</keyword>
</DOC>